This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

Provided herein are compositions and methods to that target microbial proteases to ameliorate the intestinal barrier dysfunction and restore mucosal integrity. They are useful to treat and prevent diseases and disorders caused by pathogenic bacteria in the gastrointestinal system of a subject.

The present invention provides a heparin-insensitive assay for measuring the quantity of Factor XIa in a sample. The present invention provides a method for measuring the concentration of Factor XIa in a plasma sample by using enzymatic heparin degradation as sample pretreatment step.

Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.

Aspects of the disclosure relate to methods and compositions useful for in vivo and/or in vitro enzyme profiling. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. In some embodiments, the disclosure provides compositions and in vitro methods for localization of enzymatic activity in a tissue sample.

Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.

Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.

The invention provides device and method for detecting infection in a body fluid, in particular in wound exudates and urine, based on protease activity. The device is founded on a detector consisting of one layer, which is an absorbent layer impregnated with a solution formed by dissolving a pH sensitive dye, such as bromothymol blue, in a gelatin solution. The method uses the device in form of a test strip for quick detection of an infection by observing a change in the color of the detector.

Diagnostic platforms for the detection of mucinous and high grade cysts in the pancreas of subjects are provided. The disclosure provides a system comprising enzyme specific substrate, that are specific for detection and/or quantification of serine protease TPP-1, the value of which corresponding to a determination of whether a mucinous cyst in the pancreas is malignant or benign. The disclosure also provides for a two-step method, in which a sample from a pancreatic cyst is determined mucinous by detection and/or quantification of aspartyl protease expression, and then the same cyst is determined high grade dysplasia or malignant by detection and/or quantification of serine protease expression.

Diagnostic platforms for the detection of mucinous and high grade cysts in the pancreas of subjects are provided. The disclosure provides a system comprising enzyme specific substrate, that are specific for detection and/or quantification of serine protease TPP-1, the value of which corresponding to a determination of whether a mucinous cyst in the pancreas is malignant or benign. The disclosure also provides for a two-step method, in which a sample from a pancreatic cyst is determined mucinous by detection and/or quantification of aspartyl protease expression, and then the same cyst is determined high grade dysplasia or malignant by detection and/or quantification of serine protease expression.